{"type": "text", "found_sections": ["STUDY OBJECTIVES AND ENDPOINTS", "Objectives", "Endpoints"], "content": {"0": {"name": "STUDY OBJECTIVES AND ENDPOINTS", "text": "", "type": "heading"}, "1": {"name": "Objectives", "text": "Primary Objective\nTo assess the safety and tolerability of axitinib in combination with MK-3475 in\npatients with previously untreated advanced RCC in order to estimate the maximum tolerated dose (MTD) and select the recommended Phase 2 dose (RP2D).\nSecondary  To evaluate the overall safety profile of axitinib in combination with MK-3475.\nTo assess the anti-tumor activity of axitinib in combination with MK-3475 in patients with advanced RCC in the first-line treatment setting.\nTo characterize the pharmacokinetics (PK) of axitinib and axitinib plus MK-3475\nwhen administered in combination and to assess the effect of MK-3475 on the PK of axitinib.\nTo characterize, using translational approaches, genes and proteins such as PD-L1,\nVEGF-A and IL-8 relevant to angiogenesis drug target pathway, renal cell carcinoma\nbiology, and sensitivity/resistance mechanisms to axitinib in combination with MK-3475 in tumor and/or blood.\nTo explore the pharmacodynamic effect of axitinib in combination with MK-3475 in \nSecondary  To evaluate the overall safety profile of axitinib in combination with MK-3475.\nTo assess the anti-tumor activity of axitinib in combination with MK-3475 in patients with advanced RCC in the first-line treatment setting.\nTo characterize the pharmacokinetics (PK) of axitinib and axitinib plus MK-3475\nwhen administered in combination and to assess the effect of MK-3475 on the PK of axitinib.\nTo characterize, using translational approaches, genes and proteins such as PD-L1,\nVEGF-A and IL-8 relevant to angiogenesis drug target pathway, renal cell carcinoma\nbiology, and sensitivity/resistance mechanisms to axitinib in combination with MK-3475 in tumor and/or blood.\nTo explore the pharmacodynamic effect of axitinib in combination with MK-3475 inTo assess the immunogenicity of MK-3475.", "type": "body"}, "2": {"name": "Endpoints", "text": "Primary Endpoint First 2 cycles (6 weeks) DLTs.\nSecondary \nAdverse events as characterized by type, frequency, severity (as graded by National \nSecondary \nAdverse events as characterized by type, frequency, severity (as graded by NationalLaboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE v.4.03) and timing. 4.03) and timing.Objective tumor response, as assessed by Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. 1.PK parameters of axitinib and MK-3475: Cmax, Tmax, AUC0-12, CL/F and V/F as data permit for axitinib and population-based PK parameters for MK-3475. Pre- and post-dose serum biomarkers (including but not limited to VEGF-A,\nVEGFR2 and IL-8) and whole blood biomarkers (including but not limited to T cell\nreceptor status).", "type": "body"}}}